PROSTATE CANCER AND PROSTATIC DISEASES

metrics 2024

Connecting research and practice for prostate health.

Introduction

PROSTATE CANCER AND PROSTATIC DISEASES, published by SpringerNature, is a prestigious international journal dedicated to advancing knowledge in the fields of cancer research, oncology, and urology, as evidenced by its Q1 rankings in 2023. Established in 1997, this journal has become a vital resource for researchers, clinicians, and healthcare professionals, offering impactful research and clinical insights on prostate health and disease. With its focus on innovative studies and comprehensive reviews, it addresses critical challenges in the management and treatment of prostate cancer, driving improvements in patient care globally. The journal's standing is further supported by its impressive Scopus rankings, placing it in the top tier of its categories. Readers can access high-quality, peer-reviewed articles that contribute significantly to ongoing medical practices and improve therapeutic strategies for prostate-related health issues.

Metrics 2024

SCIMAGO Journal Rank1.71
Journal Impact Factor5.10
Journal Impact Factor (5 years)4.80
H-Index78
Journal IF Without Self5.10
Eigen Factor0.01
Normal Eigen Factor1.45
Influence1.49
Immediacy Index1.00
Cited Half Life4.00
Citing Half Life4.80
JCI1.26
Total Documents1953
WOS Total Citations4090
SCIMAGO Total Citations14550
SCIMAGO SELF Citations555
Scopus Journal Rank1.71
Cites / Document (2 Years)4.15
Cites / Document (3 Years)4.37
Cites / Document (4 Years)4.39

Metrics History

Rank 2024

Scopus

Urology in Medicine
Rank #6/120
Percentile 95.00
Quartile Q1
Oncology in Medicine
Rank #60/404
Percentile 85.15
Quartile Q1
Cancer Research in Biochemistry, Genetics and Molecular Biology
Rank #51/230
Percentile 77.83
Quartile Q1

IF (Web Of Science)

ONCOLOGY
Rank 65/322
Percentile 80.00
Quartile Q1
UROLOGY & NEPHROLOGY
Rank 12/126
Percentile 90.90
Quartile Q1

JCI (Web Of Science)

ONCOLOGY
Rank 56/322
Percentile 82.61
Quartile Q1
UROLOGY & NEPHROLOGY
Rank 19/126
Percentile 84.92
Quartile Q1

Quartile History

Similar Journals

World Journal of Mens Health

Innovating research for a healthier male population.
Publisher: KOREAN SOC SEXUAL MEDICINE & ANDROLOGYISSN: 2287-4208Frequency: 4 issues/year

World Journal of Men's Health, published by the Korean Society for Sexual Medicine and Andrology, stands at the forefront of research in urology, reproductive medicine, and public health. This open-access journal, which has been serving the global medical community since 2011, provides a platform for high-quality, peer-reviewed articles spanning various disciplines, including aging, health policy, and pharmacology. With impressive rankings in multiple categories—such as Q1 in Urology and Q2 in Reproductive Medicine—the journal is recognized for its impactful contributions to advancing knowledge and practice. The ISSN 2287-4208 and E-ISSN 2287-4690 ensure its broad visibility and accessibility. The journal's commitment to disseminating vital research findings makes it an essential resource for researchers, practitioners, and students dedicated to improving men's health worldwide. With its editorial office located at Pusan National University Medical School, Dept of Urology, Busan, South Korea, it continues to enrich the academic and clinical landscape.

Oncology Letters

Unveiling the Latest in Cancer Research and Innovations
Publisher: SPANDIDOS PUBL LTDISSN: 1792-1074Frequency: 12 issues/year

Oncology Letters is a prominent academic journal dedicated to disseminating high-quality research in the fields of oncology and cancer research. Published by SPANDIDOS PUBL LTD and based in Greece, this journal has established a significant presence since its inception in 2010 and continues to contribute to the scientific community with a focus on both clinical and experimental oncology. Notably, it holds a respectable Q3 ranking in the categories of Cancer Research and Oncology as of 2023, highlighting its relevance and contribution to these critical fields. With a Scopus rank of #139/404 in Medicine – Oncology and #117/230 in Biochemistry, Genetics, and Molecular Biology – Cancer Research, Oncology Letters serves as a valuable platform for researchers, professionals, and students alike to explore emerging findings and innovative treatment approaches. Though it operates within a traditional subscription model, this journal prides itself on fostering accessible and impactful discourse in oncology, making it an essential resource for those committed to advancing cancer research and improving patient care.

Prostate Cancer

Elevating knowledge, enhancing lives in prostate cancer.
Publisher: HINDAWI LTDISSN: 2090-3111Frequency: 1 issue/year

Prostate Cancer is a leading peer-reviewed Open Access journal published by HINDAWI LTD, dedicated to advancing the field of urology and oncology through high-quality research and innovative studies. Established in 2011, this journal serves as a vital platform for disseminating findings related to prostate cancer diagnostics, treatment strategies, and patient care, striving to collaborate and connect researchers from around the globe. With an impact factor reflective of its critical input in the scientific community, the journal showcases compelling manuscripts, reviews, and case reports that are accessible to a wide audience given its open access policy. Located in London, England, Prostate Cancer has made significant strides in its category quartiles, achieving Q4 in Cancer Research and Q3 in both Oncology and Urology as of 2023, reflecting its growing relevance and readership. With Scopus rankings indicating its position within the broader medical fields, the journal is a valuable resource for researchers, professionals, and students alike, contributing to the collective effort to improve outcomes in prostate cancer research and treatment.

Prostate International

Connecting researchers and practitioners for a healthier future.
Publisher: ELSEVIER INCISSN: 2287-8882Frequency: 4 issues/year

Prostate International is a leading open-access journal published by Elsevier Inc, dedicated to advancing research and knowledge in the field of urology, particularly focusing on prostate health and disease. Since its inception in 2013, the journal has preserved its commitment to disseminating high-quality, peer-reviewed articles that contribute significantly to clinical practices and scientific understanding. With an impressive Q1 ranking in urology and a current position as rank #35/120 among urology journals in Scopus, it occupies a prominent place in the academic landscape, ensuring that cutting-edge research reaches a broad audience. The journal's open-access policy enhances visibility and accessibility, fostering collaboration among researchers, healthcare professionals, and students. With the range of topics covered, from innovative treatments to diagnostic advancements, Prostate International serves as a vital resource for those committed to improving patient outcomes and driving the future of urological health.

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

Unveiling new horizons in urologic oncology research.
Publisher: ELSEVIER SCIENCE INCISSN: 1078-1439Frequency: 12 issues/year

Urologic Oncology - Seminars and Original Investigations is a premier journal published by Elsevier Science Inc, dedicated to advancing the field of urologic oncology through high-quality, peer-reviewed research and insightful scholarly discussions. With an ISSN of 1078-1439 and an E-ISSN of 1873-2496, this journal has established itself as a vital resource for professionals, researchers, and students alike since its inception in 1995. Currently holding a Q2 ranking in Oncology and a prestigious Q1 in Urology for 2023, it ranks 28th out of 120 in Urology and 177th out of 404 in Oncology within Scopus, underscoring its relevance and impact in these critical fields. While the journal operates under a subscription model, it continues to deliver compelling and transformative research aimed at enhancing patient outcomes in urologic oncology. With a focus on innovative therapies, diagnostic advancements, and clinical trials, the journal contributes significantly to ongoing dialogue and development in urologic health care.

Clinical Lung Cancer

Leading the way in comprehensive lung cancer exploration.
Publisher: CIG MEDIA GROUP, LPISSN: 1525-7304Frequency: 6 issues/year

Clinical Lung Cancer is a prestigious journal published by CIG MEDIA GROUP, LP, dedicated to advancing the field of oncology and pulmonary medicine since its establishment in 2000. With an impressive impact factor and high ranking within its fields—achieving Q1 status in Oncology and Pulmonary and Respiratory Medicine in 2023—this journal serves as a vital resource for researchers, clinicians, and students alike. Covering a wide scope of topics related to lung cancer, Clinical Lung Cancer offers a platform for innovative studies, clinical trials, and comprehensive reviews that contribute to both theory and practice. While it operates on a subscription basis, the quality of content is reflected in its ranked status within the top quartile of cancer research journals. This journal plays a critical role in shaping the future of lung cancer research and treatment, making it an essential destination for those looking to stay at the forefront of the field.

Breast Journal

Transforming knowledge into practice for better outcomes.
Publisher: WILEY-HINDAWIISSN: 1075-122XFrequency: 1 issue/year

The Breast Journal, published by Wiley-Hindawi, is a distinguished Open Access journal dedicated to the fields of internal medicine, oncology, and surgery with a particular focus on breast health and disease. Since its inception in 1995, the journal has become an essential resource for researchers and clinicians, facilitating the dissemination of high-quality research and innovative clinical practices. With an impact factor reflecting robust scholarly influence and a ranking in the Q3 quartile for both internal medicine and oncology, as well as Q2 in surgery, it showcases significant contributions that advance knowledge and improve patient outcomes. Offering unparalleled access to its articles, The Breast Journal aims to support a global audience in exploring the multifaceted challenges and breakthroughs in breast-related health, making it a vital platform for shared learning and scientific discourse.

Actas Urologicas Espanolas

Leading the Way in Urological Innovations
Publisher: ELSEVIER ESPANAISSN: 0210-4806Frequency: 10 issues/year

Actas Urologicas Espanolas is a prestigious journal published by Elsevier España, dedicated to the field of Urology. Established in 1977, this journal has significantly contributed to advancing knowledge and research in urological medicine and surgery, spanning a comprehensive scope that includes clinical studies, surgical techniques, and the latest innovations in the treatment of urological diseases. With an impact factor reflecting its critical role in the academic community, it is ranked Q3 in the Urology category as of 2023, placing it amongst the valuable resources for professionals and researchers. The journal is indexed under Scopus, achieving a commendable rank of #70 out of 120 in the Medicine-Urology category, situating it within the 42nd percentile. As a significant platform for sharing advancements and findings, it encourages submissions that enhance urological care and improve patient outcomes. Although not an Open Access journal, the publication remains vital for those looking to stay updated on the latest developments in urology. For more details, visit their office located at CALLE DE ZURBANO, 76-4TH FLR LEFT, MADRID, 28010, SPAIN.

LANCET ONCOLOGY

Leading the way in oncology research and clinical excellence.
Publisher: ELSEVIER SCIENCE INCISSN: 1470-2045Frequency: 12 issues/year

The Lancet Oncology is a premier peer-reviewed journal published by Elsevier Science Inc., recognized as a leading authority in the field of oncology. With an ISSN of 1470-2045 and E-ISSN 1474-5488, this esteemed journal boasts an impressive 2023 impact factor placing it in the Q1 category of oncology—reflecting its role as a critical resource for cutting-edge research. The journal publishes high-quality articles covering novel scientific discoveries, clinical advancements, and public health issues related to cancer treatment and prevention. It is ranked #5 out of 404 in the Scopus Medicine _ Oncology category, demonstrating its influence and relevance in the field, with an outstanding rank in the 98th percentile. Operating from its base in the United Kingdom, The Lancet Oncology spans a comprehensive timeframe from 2000 to 2024, making it a vital repository of oncology literature. Although it does not primarily operate on an open-access model, its significant subscription base ensures that a wealth of knowledge is accessible to researchers, professionals, and students alike, fostering a profound understanding and advancement in oncology.

Frontiers in Cardiovascular Medicine

Advancing Cardiovascular Knowledge for a Healthier Tomorrow.
Publisher: FRONTIERS MEDIA SAISSN: 2297-055XFrequency: 1 issue/year

Frontiers in Cardiovascular Medicine is a leading open-access journal published by FRONTIERS MEDIA SA, dedicated to advancing research in the field of cardiology and cardiovascular medicine. Since its inception in 2014, the journal has become a vital platform for the dissemination of high-quality research, boasting a commendable Q2 rank in the 2023 category for Cardiology and Cardiovascular Medicine. With a focus on promoting innovative studies and clinical insights, Frontiers in Cardiovascular Medicine facilitates open access to its content, allowing researchers, healthcare professionals, and students from around the globe to engage with the latest findings which are critical for the advancement of cardiovascular health. The journal's significant presence in the academic landscape, as indicated by its Scopus ranking (161/387 and 58th percentile), underscores its importance as a research outlet in this essential field. Located in Lausanne, Switzerland, the journal continues to support the global cardiovascular community by encouraging collaboration and knowledge sharing to address the challenges faced in cardiovascular medicine today.